MS Pharma announced that Olayan Financing Company has made a minority equity investment in the company to support its next phase of growth across Saudi Arabia and the wider MENA region.
The transaction involves MS Pharma issuing new share capital in exchange for a substantial cash investment from OFC, resulting in OFC acquiring a minority stake in the company.
The investment will strengthen MS Pharma’s financial position and support the expansion of its biosimilars portfolio, manufacturing capabilities, and supply chain resilience across the region.
Ghiath Sukhtian said the partnership reflects confidence in the company’s growth strategy and will bring added value through OFC’s operational expertise and strong presence in Saudi Arabia.
Commenting on the new partnership, Ghiath Sukhtian, Chairman of MS Pharma, said: “We are delighted and honored to welcome OFC as partners in the company. Their global operational and investing expertise, as well as their deep roots in KSA, will add significant value to MS Pharma and benefit all our stakeholders.”
Kalle Kaend, CEO of MS Pharma, added: “This investment comes at an exciting inflection point for MS Pharma. It will enable us to deepen our expertise in biologics, expand our reach in KSA and the wider MENA region, and accelerate our growth in biosimilars.”
Kalle Kaend said the investment comes at a key stage in the company’s expansion plans and will help accelerate growth in biologics and biosimilars across the MENA region.
Nabeel Al-Amudi stated that MS Pharma has established itself as a leading pharmaceutical platform in the region with strong capabilities in generics and biologics.
Nabeel Al-Amudi, CEO of Olayan Financing Company, remarked: “MS Pharma has established itself as a leading pharmaceutical platform in the region, with strong capabilities across generics and biologics. We are pleased to partner with the company at this stage of its growth and look forward to supporting its continued expansion in Saudi Arabia and across the MENA region, in alignment with our long-term investment philosophy.”
The partnership builds on MS Pharma’s leadership in biosimilars, particularly in Saudi Arabia, where its biologics facility became the first in the Kingdom to receive SFDA GMP approval for biologics manufacturing. The company also plans to become the first supplier of locally manufactured biologics to the Saudi market this year, supporting the goals of Saudi Arabia’s National Biotechnology Strategy and Vision 2030.
Headquartered in Amman, Jordan, MS Pharma operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia and employs more than 2,000 people across 12 countries.
